Apollo Endosurgery Inc.
| NASDAQ: APEN | Healthcare / Medical Devices & Instruments / USA |
| 9.91 | +0.0100 | +0.10% | Vol 452.80K | 1Y Perf 60.19% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 9.90 | ASK | 9.93 | ||
| Open | 9.88 | Previous Close | 9.90 | ||
| Pre-Market | - | After-Market | 9.90 | ||
| - - | -0.01 -0.10% |
| Target Price | 11.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 11.00 | Finscreener Ranking | + 38.88 | |
| Insiders Trans % 3/6/12 mo. | -/100/40 | Value Ranking | ★ 41.54 | |
| Insiders Value % 3/6/12 mo. | -/100/84 | Growth Ranking | + 29.63 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/84 | Income Ranking | — - | |
| Price Range Ratio 52W % | 94.27 | Earnings Rating | Neutral | |
| Market Cap | 471.21M | Earnings Date | 28th Mar 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.28 | |
| Beta | 2.27 |
Today's Price Range 9.879.92 | 52W Range 3.4910.30 | 5 Year PE Ratio Range -3.20-0.2000 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.30% | ||
| 1 Month | -0.40% | ||
| 3 Months | -0.20% | ||
| 6 Months | 92.43% | ||
| 1 Year | 60.19% | ||
| 3 Years | 390.59% | ||
| 5 Years | 49.47% | ||
| 10 Years | -97.40% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -53.59 | |||
ROE last 12 Months | -192.68 | |||
ROA (5Y Avg) | -15.02 | |||
ROA last 12 Months | -46.18 | |||
ROC (5Y Avg) | -33.40 | |||
ROC last 12 Months | -47.26 | |||
Return on invested Capital Q | -10.84 | |||
Return on invested Capital Y | -7.20 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -9.40 | ||||
| 9.74 | ||||
| 7.41 | ||||
| 6.00 | ||||
| -17.80 | ||||
| -0.64 | ||||
| 12.24 | ||||
| 1.02 | ||||
| 399.19M | ||||
| Forward PE | -11.48 | |||
| PEG | -0.74 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.80 | ||||
| 6.00 | ||||
| 0.56 | ||||
| 1.28 | ||||
| -4.10 | ||||
| Leverage Ratio | 2.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 56.00 | ||||
| -45.30 | ||||
| -41.10 | ||||
| -57.70 | ||||
| -54.53 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 55.54M | ||||
| 1.33 | ||||
| 3.31 | ||||
| -5.32 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.21 | -0.28 | -33.33 |
| Q02 2022 | -0.21 | -0.26 | -23.81 |
| Q01 2022 | -0.21 | -0.21 | 0.00 |
| Q04 2021 | -0.20 | -0.27 | -35.00 |
| Q03 2021 | -0.30 | -0.23 | 23.33 |
| Q02 2021 | -0.17 | -0.11 | 35.29 |
| Q01 2021 | -0.19 | -0.17 | 10.53 |
| Q04 2020 | -0.21 | -0.14 | 33.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.21 | 4.55 | Positive |
| 12/2022 FY | -0.97 | -410.53 | Negative |
| 3/2023 QR | -0.19 | 0.00 | - |
| 12/2023 FY | -0.86 | 6.52 | Positive |
| Next Report Date | 28th Mar 2023 |
| Estimated EPS Next Report | -0.21 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 452.80K |
| Shares Outstanding | 47.55K |
| Shares Float | 33.98M |
| Trades Count | 2.29K |
| Dollar Volume | 4.49M |
| Avg. Volume | 1.08M |
| Avg. Weekly Volume | 704.47K |
| Avg. Monthly Volume | 1.12M |
| Avg. Quarterly Volume | 1.40M |
Apollo Endosurgery Inc. (NASDAQ: APEN) stock closed at 9.91 per share at the end of the most recent trading day (a 0.1% change compared to the prior day closing price) with a volume of 452.80K shares and market capitalization of 471.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 217 people. Apollo Endosurgery Inc. CEO is K. Todd Newton.
The one-year performance of Apollo Endosurgery Inc. stock is 60.19%, while year-to-date (YTD) performance is -0.6%. APEN stock has a five-year performance of 49.47%. Its 52-week range is between 3.49 and 10.3, which gives APEN stock a 52-week price range ratio of 94.27%
Apollo Endosurgery Inc. currently has a PE ratio of -9.40, a price-to-book (PB) ratio of 9.74, a price-to-sale (PS) ratio of 7.41, a price to cashflow ratio of 6.00, a PEG ratio of 2.32, a ROA of -46.18%, a ROC of -47.26% and a ROE of -192.68%. The company’s profit margin is -54.53%, its EBITDA margin is -41.10%, and its revenue ttm is $55.54 Million , which makes it $1.33 revenue per share.
Of the last four earnings reports from Apollo Endosurgery Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Apollo Endosurgery Inc.’s next earnings report date is 28th Mar 2023.
The consensus rating of Wall Street analysts for Apollo Endosurgery Inc. is Hold (3), with a target price of $11, which is +11.00% compared to the current price. The earnings rating for Apollo Endosurgery Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apollo Endosurgery Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apollo Endosurgery Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.15, ATR14 : 0.04, CCI20 : -60.61, Chaikin Money Flow : -0.04, MACD : 0.00, Money Flow Index : 37.87, ROC : -0.20, RSI : 50.86, STOCH (14,3) : 54.55, STOCH RSI : 0.50, UO : 57.96, Williams %R : -45.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apollo Endosurgery Inc. in the last 12-months were:
Apollo Endosurgery Inc.
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focusses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include ORBERA, LAP-BAND and OverStitch.
CEO: K. Todd Newton
Telephone: +1 512 279-5100
Address: 1120 S. Capital of Texas Highway, Austin 78746, TX, US
Number of employees: 217
